Prevalence and characterisation of carbapenemase encoding genes in multidrug-resistant Gram-negative bacilli

被引:27
|
作者
Haji, Sayran Hamad [1 ]
Aka, Safaa Toma Hanna [1 ]
Ali, Fattma A. [2 ]
机构
[1] Hawler Med Univ, Coll Pharm, Dept Pharmacognosy, Erbil, Iraq
[2] Hawler Med Univ, Coll Hlth Sci, Dept Med Microbiol, Erbil, Iraq
来源
PLOS ONE | 2021年 / 16卷 / 11期
关键词
MOLECULAR CHARACTERIZATION; BETA-LACTAMASE; ESCHERICHIA-COLI; 1ST REPORT; ENTEROBACTERIACEAE; INFECTIONS; PNEUMONIAE; CARRIAGE;
D O I
10.1371/journal.pone.0259005
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Emerging worldwide in the past decade, there has been a significant increase in multidrug-resistant bacteria from serious nosocomial infections, especially carbapenemase-producing Gram-negative bacilli that have emerged worldwide. The objective of this study is to investigate carbapenem resistance in Gram-negative bacilli bacteria using phenotypic detection, antimicrobial resistance profiles and genotypic characterisation methods. Methods 200 Gram-negative bacilli isolates were collected from different clinical specimens. All clinical samples were exposed to isolation and identification of significant pathogens applying bacteriological examination and an automated Vitek-2 system. The isolates were subjected to susceptibility tests by the Vitek-2 automated system and those isolates that were resistant to beta-lactam drugs, including carbapenems, third-generation cephalosporines or cefoxitin, were selected for phenotyping using Carba plus disc system assay for detection of carbapenemase-producing isolates. These isolates were further confirmed by molecular detection. PCR was used for the detection carbapenem-resistant genes (OXA-48, IMP, NDM, VIM, and KPC). Results 110 (55%) of 200 Gram-negative bacilli were identified as beta-lactam-resistant isolates. The frequency of carbapenem-resistant isolates was calculated to be 30.9% (n = 34/110). A collection totalling 65/110 (59%) isolates were identified as carbapenemase producers by phenotypic method. Moreover, among the 65 carbapenemase-producing Gram-negative isolates with a positive phenotype-based result, 30 (46%), 20 (30%) and 18 (27%) isolates were positive for OXA-48, KPC and MBL enzymes, respectively, as well as the production of 27% of AmpC with porin loss. Tigecycline was the most effective antibiotic that affected 70% of MDR isolates, but high rates of resistance were detected to other tested antimicrobials. Of interest, a high incidence of MDR, XDR and PDR profiles were observed among all carbapenemase-producing isolates. 36% (24/65) of the tested isolates were MDR to 3 to 5 antimicrobial classes. 29% (17/65) of the recovered isolates were XDR to 6 to 7 antimicrobial classes. Alarmingly, 24% (16/65) of isolates displayed PDR to all the tested 8 antimicrobial classes. Genotype assay, including 53 phenotypically confirmed carbapenemase-producing isolates of Gram-negative bacilli, found 51(96%) isolates were harbouring one or more genes. The most common carbapenemase gene was bla(NDM) 83% (44/53) followed by bla(OXA-48) 75% (40/53), bla(VIM) 49% (26/53) and bla(IMP) 43% (23/53), while the gene bla(KPC) was least frequent 7% (4/53). 92% (46/51) of isolates were involved in the production of more than one carbapenemase gene. Conclusion This study demonstrated the emergence of carbapenemase-producing Gram-negative pathogens implicated in healthcare-related infections. Accurate identification of carbapenem-resistant bacterial pathogens is essential for patient treatment, as well as the development of appropriate contamination control measures to limit the rapid spread of pathogens. Tigecycline exhibited potent antimicrobial activity against MDR, XDR and PDR-producing strains that establish a threatening alert which indicates the complex therapy of infections caused by these pathogens.
引用
收藏
页数:22
相关论文
共 50 条
  • [1] Prevalence of Oxacillinase Genes in Clinical Multidrug-Resistant Gram-Negative Bacteria
    Ahmed, Omar B.
    Bamaga, Majid A.
    CLINICAL LABORATORY, 2025, 71 (03) : 465 - 471
  • [2] Multidrug-Resistant Gram-Negative Bacilli: Infection Control Implications
    Adler, Amos
    Friedman, N. Deborah
    Marchaim, Dror
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2016, 30 (04) : 967 - +
  • [3] Facing the challenge of multidrug-resistant gram-negative bacilli in Australia
    Harris, Patrick
    Paterson, David
    Rogers, Benjamin
    MEDICAL JOURNAL OF AUSTRALIA, 2015, 202 (05) : 243 - +
  • [4] Carriage of multidrug-resistant Gram-negative bacilli: duration and risk factors
    Herrera, S.
    Torralbo, B.
    Herranz, S.
    Bernal-Maurandi, J.
    Rubio, E.
    Pitart, C.
    Fortes, I.
    Valls, S.
    Rodriguez, L.
    Santana, G.
    Bodro, M.
    Garcia-Vidal, C.
    Hernandez-Meneses, M.
    Puerta, P.
    Morata, L.
    Villella, A.
    Bertran, M. J.
    Brey, M.
    Soriano, A.
    Del Rio, A.
    Martinez, J. A.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2023, 42 (05) : 631 - 638
  • [5] Risk factors and outcomes for multidrug-resistant Gram-negative bacilli bacteremia
    Patolia, Swati
    Abate, Getahun
    Patel, Nirav
    Patolia, Setu
    Frey, Sharon
    THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE, 2018, 5 (01) : 11 - 18
  • [6] New treatments for multidrug-resistant nonfermenting Gram-negative bacilli Infections
    Chumbita, Mariana
    Monzo-Gallo, Patricia
    Lopera-Marmol, Carlos
    Francesco Aiello, Tommaso
    Puerta-Alcalde, Pedro
    Garcia-Vidal, Carolina
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2022, 35 : 51 - 53
  • [7] Carriage of multidrug-resistant Gram-negative bacilli: duration and risk factors
    S. Herrera
    B. Torralbo
    S. Herranz
    J. Bernal-Maurandi
    E. Rubio
    C. Pitart
    I. Fortes
    S. Valls
    L. Rodríguez
    G. Santana
    M. Bodro
    C. Garcia-Vidal
    M. Hernández-Meneses
    P. Puerta
    L. Morata
    A. Villella
    M. J. Bertran
    M. Brey
    A. Soriano
    A. Del Río
    J. A. Martinez
    European Journal of Clinical Microbiology & Infectious Diseases, 2023, 42 : 631 - 638
  • [8] The current state of multidrug-resistant gram-negative bacilli in north America
    Nicasio, Anthony M.
    Kuti, Joseph L.
    Nicolau, David P.
    PHARMACOTHERAPY, 2008, 28 (02): : 235 - 249
  • [9] In vitro activity of arbekacin against multidrug-resistant gram-negative bacilli
    Albano, Mariana
    Fleischmann, Wim Alexander
    Greenwood-Quaintance, Kerryl E.
    Patel, Robin
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2021, 54 (06) : 1118 - 1121
  • [10] Current Epidemiology of Multidrug-Resistant Gram-Negative Bacilli in the United States
    Kallen, Alexander J.
    Srinivasan, Arjun
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2010, 31 : S51 - S54